Skip to main
ARDX
ARDX logo

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. demonstrates strong financial momentum, particularly with the recently reported 4Q24 net sales of IBSRELA reaching $53.8 million, reflecting a robust quarterly growth of 32.5% compared to 3Q24, and an overall annual total of $158.3 million. Additionally, XPHOZAH net sales for the same quarter totaled $57.2 million, marking an 11.1% increase from the previous quarter and contributing to a successful first year total of $160.9 million. The company is poised for further growth in 2025, projecting IBSRELA net sales between $240 million and $250 million, which translates to an impressive annual growth rate of approximately 52% to 58%.

Bears say

Ardelyx Inc. is facing a cautionary outlook due to projected stagnation in XPHOZAH's weekly prescriptions, remaining flat at 750, which anchors anticipated net sales for 1Q25 at only $26.7 million. The company reported a significant net loss of $39.1 million for FY2024, compounded by high operating expenses totaling approximately $361.6 million in R&D, SG&A, and cost of goods sold. Additionally, the potential deterioration of XPHOZAH's gross-to-net and risks related to market size, competition, and intellectual property could undermine future growth prospects, contributing to a negative sentiment surrounding the stock.

Ardelyx (ARDX) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Buy based on their latest research and market trends.

According to 14 analysts, Ardelyx (ARDX) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.